文献速递甲状腺疾病

患者持续症状、临床医生人口学特征及地理经济因素与欧洲甲状腺专家对甲状腺功能减退症治疗选择相关:THESIS协作

Patients' Persistent Symptoms, Clinician Demographics, and Geo-Economic Factors Are Associated with Choice of Therapy for Hypothyroidism by European Thyroid Specialists: The "THESIS" Collaboration.
PubMed 文献 · Thyroid · 2024-03-22

该调查邀请28个国家17247名甲状腺专家参与在线问卷,应答率32.9%(6058名)。98.3%的应答者首选左甲状腺素(LT4)作为初始治疗,40.0%的应答者在患者TSH正常但持续有症状时选择LT4+碘塞罗宁(LT3)联合治疗,该选择与女性、高工作量执业及高人均国民总收入国家相关。

要点

  • 98.3%的应答者首选LT4作为甲状腺功能减退症的初始治疗。
  • 75.4%的应答者报告TSH正常而持续症状影响最多10.0%的患者,28.4%报告过去5年此类情况呈增加趋势。
  • 40.0%的应答者对TSH正常但持续症状的患者选择LT4+LT3联合治疗。

核心结论

  • 医生报告的患者不满意比例似乎低于既往调查中甲状腺功能减退症患者所描述的水平。
  • 尽管医生通常将持续类甲减症状归因于非内分泌原因,且联合治疗不优于LT4治疗的证据存在,欧洲甲状腺专家仍频繁使用LT4+LT3治疗持续类甲减症状。
  • 不满意患者对医生施加使用含LT3治疗的压力可能是原因之一。
  • 治疗选择与临床医生人口学特征及欧洲地理经济因素的关联是新信息,需进一步研究。

研究设计与样本

  • 邀请28个国家的17247名甲状腺专家参与在线问卷调查,问卷包括应答者人口学数据及对持续症状甲减患者的治疗选择,并纳入各国地理经济数据进行分析。
  • 应答率为32.9%(17247名受邀者中6058名应答)。

主要发现

  • 多数应答者(98.3%)首选左甲状腺素(LT4)作为初始治疗。
  • 75.4%的应答者报告,在接受LT4治疗且血清促甲状腺激素(TSH)正常的情况下,持续症状影响最多10.0%的患者;28.4%的应答者报告过去5年此类情况呈增加趋势。
  • 对患者持续症状的主要解释为心理社会因素(77.1%)、合并症(69.2%)和不切实际的患者期望(61.0%)。
  • 40.0%的应答者对TSH正常但主诉持续症状的患者选择LT4+碘塞罗宁(LT3)联合治疗。
  • 该选项更多被女性甲状腺专家、高工作量执业者及在人均国民总收入较高国家工作的专家选择。

局限性

  • 原文结论指出治疗选择与临床医生人口学特征及欧洲地理经济因素的关联是新信息,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Hypothyroidism is common, however, aspects of its treatment remain controversial. Our survey aimed at documenting treatment choices of European thyroid specialists and exploring how patients' persistent symptoms, clinician demographics, and geo-economic factors relate to treatment choices. Methods: Seventeen thousand two hundred forty-seven thyroid specialists from 28 countries were invited to participate in an online questionnaire survey. The survey included respondent demographic data and treatment choices for hypothyroid patients with persistent symptoms. Geo-economic data for each country were included in the analyses. Results: The response rate was 32.9% (6058 respondents out of 17,247 invitees). Levothyroxine (LT4) was the initial treatment preferred by the majority (98.3%). Persistent symptoms despite normal serum thyrotropin (TSH) while receiving LT4 treatment were reported to affect up to 10.0% of patients by 75.4% of respondents, while 28.4% reported an increasing such trend in the past 5 years. The principal explanations offered for patients' persistent symptoms were psychosocial factors (77.1%), comorbidities (69.2%), and unrealistic patient expectations (61.0%). Combination treatment with LT4+liothyronine (LT3) was chosen by 40.0% of respondents for patients who complained of persistent symptoms despite a normal TSH. This option was selected more frequently by female thyroid specialists, with high-volume practice, working in countries with high gross national income per capita. Conclusions: The perception of patients' dissatisfaction reported by physicians seems lower than that described by hypothyroid patients in previous surveys. LT4+LT3 treatment is used frequently by thyroid specialists in Europe for persistent hypothyroid-like symptoms even if they generally attribute such symptoms to nonendocrine causes and despite the evidence of nonsuperiority of the combined over the LT4 therapy. Pressure by dissatisfied patients on their physicians for LT3-containing treatments is a likely explanation. The association of the therapeutic choices with the clinician demographic characteristics and geo-economic factors in Europe is a novel information and requires further investigation.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Attanasio R, Žarković M, Papini E, et al. Patients' Persistent Symptoms, Clinician Demographics, and Geo-Economic Factors Are Associated with Choice of Therapy for Hypothyroidism by European Thyroid Specialists: The "THESIS" Collaboration. Thyroid. 2024. PMID: 38368541. doi:10.1089/thy.2023.0580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。